Drug profile · INN
doxorubicin
ADRIAMYCIN
doxorubicin (ADRIAMYCIN) is a dna topoisomerase ii alpha inhibitor. Associated with Pfizer Australia Pty Ltd.
EMA: approved TGA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01DB
Patents linked 0
Pipeline programs 109
News articles 1
Drug details — doxorubicin
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 109
- Data quality
- 0.83
Quick answer
doxorubicin (ADRIAMYCIN) is a dna topoisomerase ii alpha inhibitor. Associated with Pfizer Australia Pty Ltd.
Key facts
INN doxorubicin
Brand ADRIAMYCIN
Mechanism DNA topoisomerase II alpha inhibitor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01DB
Originator Pfizer Australia Pty Ltd
Mechanism of action
DNA topoisomerase II alpha inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is doxorubicin?
doxorubicin (ADRIAMYCIN) is a dna topoisomerase ii alpha inhibitor. Associated with Pfizer Australia Pty Ltd.
What is the brand name for doxorubicin?
ADRIAMYCIN is a marketed brand name for doxorubicin. Check FDA Drugs@FDA for the current US label holder and prescribing information.